MedTrace Logo

Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy

NCT04069325 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2019-08-30

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.

Conditions

  • Gout Flare

Interventions

DRUG

simiaowan

pills, 6g twice daily (BID), oral, 12 weeks

DRUG

placebo

pills, 6g twice daily (BID), oral, 12 weeks

DRUG

febuxostat

tablets, 40 mg once daily (QD), oral, 12 weeks

Sponsors & Collaborators

  • Affiliated Hospital of Nanjing University of Chinese Medicine

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Jiang Quan, Doctor · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-07-28
Completion
2020-07-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04069325 on ClinicalTrials.gov